Eli Lilly and Co.

Lilly cites 'deep concerns' over China kickback allegations

August 22, 2013
Bloomberg News, Associated Press
Eli Lilly and Co. said it is investigating allegations its employees paid Chinese doctors at least $4.9 million in bribes and kickbacks to promote the sales of two diabetes drugs.
More

Lilly lung cancer drug raises patient survival in trial

August 13, 2013
Bloomberg News
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
More

Lilly's new strategy built around head-to-head drug trialsRestricted Content

August 10, 2013
J.K. Wall
Lilly has set up not one, not two, but five head-to-head trials of its experimental drug dulaglutide against other leading diabetes therapies. So far, dulaglutide’s record is four wins, no losses.
More

PROXY CORNER: Eli Lilly and Co.Restricted Content

August 3, 2013
Indianapolis-based Eli Lilly and Co. discovers, develops, manufactures and sells pharmaceutical products for humans and animals.
More

Lilly shares rise after drugmaker reports solid second quarter

July 24, 2013
Bloomberg News, J.K. Wall
Strong sales and penny-pinching helped Eli Lilly and Co. beat Wall Street’s expectations in the second quarter, leading the company to raise its profit forecast for the year.
More

Lilly freezes pay for workers, executives

July 17, 2013
Bloomberg News
The pay freeze will save $400 million through 2016, said a spokesman for the Indianapolis-based company. Lilly won't give pay raises to executives, supervisors or most employees. Some bonuses will also be reduced.
More

Lilly aims potential Alzheimer’s drug at early patients

July 12, 2013
Bloomberg News
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.
More

Lilly drug for Alzheimer's gets limited Medicare coverage

July 8, 2013
Bloomberg News, Associated Press
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
More

Lilly's Lechleiter back at helm after health scare

July 8, 2013
Associated Press
Eli Lilly and Co. Chairman and CEO John Lechleiter is back to full-time work after taking a leave in May to have surgery for a dilated aorta, the company announced Monday morning.
More

Miami man pleads guilty to $90M Lilly drug heist

July 1, 2013
Associated Press
Thieves broke into the Connecticut warehouse of Indianapolis-based Eli Lilly and Co. in 2010 by scaling an exterior wall and cutting a hole in the roof. They lowered themselves to the floor and disabled alarms before using a forklift to load pallets of drugs into a getaway vehicle.
More

Feds mull covering Alzheimer's test that uses Lilly's Amyvid

July 1, 2013
Bloomberg News
The $3,000 test for the first time accurately identifies the signature brain plaques of the debilitating disease.
More

Lilly’s experimental diabetes drug helps patients lose weight

June 24, 2013
Bloomberg News
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
More

Lilly’s Zyprexa injection probed by FDA after deaths

June 18, 2013
Bloomberg News
Eli Lilly and Co.’s injectable form of the antipsychotic Zyprexa is being investigated by U.S. regulators after two patients died three to four days after receiving the drug.
More

Drugmakers may face ‘pay for delay’ suits, high court rules

June 18, 2013
Bloomberg News
Drug companies like Eli Lilly and Co. can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.
More

Lilly to take over development of diabetes drug

June 17, 2013
Associated Press
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. at least $7 million and up to as much as $247 million to take over the development of a potential diabetes treatment.
More

Most of Indiana's largest public companies enjoyed strong 2012Restricted Content

June 15, 2013
Angie's List turned a profit for the first time in nearly two decades.
More

Lilly halts trial of experimental Alzheimers drug

June 14, 2013
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
More

Drug sold by Lilly tops Avastin in colon cancer survival study

June 3, 2013
Bloomberg News
Patients who got Erbitux together with chemotherapy as a first-line treatment lived about four months longer than those who got Avastin with chemotherapy, according to the 592-person study.
More

Endowment assets soar $1.2B as Lilly shares climb

May 30, 2013
Andrea Muirragui Davis
Lilly Endowment awarded $230 million in 2012, mostly to Indiana groups. Its fortunes still are largely tied to the value of Eli Lilly and Co. stock, despite an effort to diversify the private foundation's holdings.
More

Lilly study: 1 in 5 Alzheimer's patients misdiagnosed

May 20, 2013
J.K. Wall
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
More

Canada’s Supreme Court won’t hear Lilly appeal on Zyprexa

May 16, 2013
Bloomberg News
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major developed countries.
More

Lechleiter's surgery to repair heart goes as planned

May 14, 2013
Bloomberg News
Eli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta is functioning as intended, the Indianapolis-based drugmaker said.
More

Lilly stops development on cancer drug after failed study

May 10, 2013
Bloomberg News
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
More

Indiana firms lose ground on Fortune 500 list

May 7, 2013
Mason King
Five of the six Hoosier firms that appear in the 2013 rankings slipped from their positions in last year's list of the largest U.S. companies.
More

Lilly CEO to step down temporarily due to surgery

May 6, 2013
J.K. Wall
John Lechleiter has been suffering from a dilated aorta, Eli Lilly and Co. said Monday. Current CFO Derica Rice will take his place until later this summer.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Really, taking someone managing the regulation of Alcohol and making himthe President of an IVY Tech regional campus. Does he have an education background?

  2. Jan, great rant. Now how about you review the report and offer rebuttal of the memo. This might be more conducive to civil discourse than a wild rant with no supporting facts. Perhaps some links to support your assertions would be helpful

  3. I've lived in Indianapolis my whole and been to the track 3 times. Once for a Brickyard, once last year on a practice day for Indy 500, and once when I was a high school student to pick up trash for community service. In the past 11 years, I would say while the IMS is a great venue, there are some upgrades that would show that it's changing with the times, just like the city is. First, take out the bleachers and put in individual seats. Kentucky Motor Speedway has individual seats and they look cool. Fix up the restrooms. Add wi-fi. Like others have suggested, look at bringing in concerts leading up to events. Don't just stick with the country music genre. Pop music would work well too I believe. This will attract more young celebrities to the Indy 500 like the kind that go to the Kentucky Derby. Work with Indy Go to increase the frequency of the bus route to the track during high end events. That way people have other options than worrying about where to park and paying for parking. Then after all of this, look at getting night lights. I think the aforementioned strategies are more necessary than night racing at this point in time.

  4. Talking about congestion ANYWHERE in Indianapolis is absolutely laughable. Sure you may have to wait in 5 minutes of traffic to travel down BR avenue during *peak* times. But that is absolutely nothing compared to actual big cities. Indy is way too suburban to have actual congestion problems. So please, never bring up "congestion" as an excuse to avoid development in Indianapolis. If anything, we could use a little more.

  5. Oh wait. Never mind.

ADVERTISEMENT